04/28/2025
3:40 PM | Olema Pharmaceuticals (Filer)
| Form ARS | |
04/28/2025
3:30 PM | Olema Pharmaceuticals (Filer)
| Form DEF 14A | |
04/28/2025
3:35 PM | Olema Pharmaceuticals (Filer)
| Form DEFA14A | |
04/15/2025
4:04 PM | BlackRock Portfolio Management LLC (Filed by)
Olema Pharmaceuticals (Subject)
| Form SCHEDULE 13G | |
03/18/2025
3:26 PM | Olema Pharmaceuticals (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
03/18/2025
3:15 PM | Olema Pharmaceuticals (Filer)
| Form 10-K
Annual report pursuant to Section 13 or 15(d) | |
03/18/2025
3:10 PM | Olema Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/05/2025
6:15 AM | Olema Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/03/2025
3:16 PM | Kovacs Shane William Charles (Reporting)
Olema Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/03/2025
3:18 PM | Mitchell Shawnte (Reporting)
Olema Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/03/2025
3:19 PM | Olema Pharmaceuticals (Issuer)
Zojwalla Naseem (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
Get the Latest News and Ratings for OLMA and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Olema Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. |
03/03/2025
3:20 PM | Myles David C. (Reporting)
Olema Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/14/2025
3:45 PM | Olema Pharmaceuticals (Subject)
Paradigm Biocapital Advisors LP (Filed by)
| Form SCHEDULE 13G/A | |
01/15/2025
11:15 PM | Olema Pharmaceuticals (Filer)
| Form EFFECT | |
01/15/2025
11:15 PM | Olema Pharmaceuticals (Filer)
| Form EFFECT | |
01/15/2025
3:44 PM | Olema Pharmaceuticals (Filer)
| Form 424B3 | |
01/15/2025
3:46 PM | Olema Pharmaceuticals (Filer)
| Form 424B5 | |
01/14/2025
5:38 PM | BIOTECHNOLOGY VALUE FUND II LP (Reporting)
BIOTECHNOLOGY VALUE FUND L P (Reporting)
Biotechnology Value Trading Fund OS LP (Reporting)
BVF GP HOLDINGS LLC (Reporting)
BVF I GP LLC (Reporting)
BVF II GP LLC (Reporting)
BVF INC/IL (Reporting)
BVF PARTNERS L P/IL (Reporting)
BVF Partners OS Ltd. (Reporting)
LAMPERT MARK N (Reporting)
Olema Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/13/2025
3:31 PM | Bain Capital Life Sciences Fund IV, L.P. (Reporting)
Bain Capital Life Sciences Investors, LLC (Reporting)
Bain Capital Life Sciences IV General Partner, LLC (Reporting)
Bain Capital Life Sciences Opportunities IV GP, LLC (Reporting)
Bain Capital Life Sciences Opportunities IV, L.P. (Reporting)
Olema Pharmaceuticals (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
01/13/2025
3:34 PM | Bain Capital Life Sciences Fund IV, L.P. (Reporting)
Bain Capital Life Sciences Investors, LLC (Reporting)
Bain Capital Life Sciences IV General Partner, LLC (Reporting)
Bain Capital Life Sciences Opportunities IV GP, LLC (Reporting)
Bain Capital Life Sciences Opportunities IV, L.P. (Reporting)
Olema Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/13/2025
3:24 PM | Bain Capital Life Sciences Opportunities IV, L.P. (Filed by)
Olema Pharmaceuticals (Subject)
| Form SCHEDULE 13G/A | |
01/13/2025
6:15 AM | Olema Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/03/2025
3:49 PM | Olema Pharmaceuticals (Filer)
| Form S-3
Registration statement under Securities Act of 1933 | |
12/18/2024
5:52 PM | Graham G. Walmsley (Reporting)
Olema Pharmaceuticals (Issuer)
| Form 4/A | |
12/17/2024
6:52 PM | Graham G. Walmsley (Reporting)
Olema Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/17/2024
6:29 PM | Olema Pharmaceuticals (Issuer)
Zojwalla Naseem (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/13/2024
3:37 PM | Logos Opportunities Fund I LP (Reporting)
Olema Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/11/2024
6:56 PM | Myles David C. (Reporting)
Olema Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/11/2024
6:56 PM | Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/11/2024
6:52 PM | Bohen Sean (Reporting)
Olema Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/11/2024
6:53 PM | Kovacs Shane William Charles (Reporting)
Olema Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/11/2024
6:54 PM | Olema Pharmaceuticals (Issuer)
Zojwalla Naseem (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/11/2024
4:19 PM | Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/11/2024
4:04 PM | Kovacs Shane William Charles (Reporting)
Olema Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/11/2024
3:27 PM | Bohen Sean (Reporting)
Olema Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/11/2024
3:30 PM | Bain Capital Life Sciences Opportunities IV, L.P. (Filed by)
Olema Pharmaceuticals (Subject)
| Form SC 13G | |
12/11/2024
3:33 PM | Olema Pharmaceuticals (Subject)
Zojwalla Naseem (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/10/2024
2:23 PM | Bohen Sean (Reporting)
Olema Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/10/2024
1:48 PM | Myles David C. (Reporting)
Olema Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/10/2024
1:14 PM | Olema Pharmaceuticals (Subject)
Zojwalla Naseem (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/10/2024
1:21 PM | Kovacs Shane William Charles (Reporting)
Olema Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
Elon Musk is all in on these robots … (Ad) Robots — built by Nvidia.
Forbes says this could be " a $24 trillion opportunity for investors."
Huang said, "The ChatGPT moment for robotics is right around the corner."
In fact, I believe these robots could impact 65 million Americans lives — this year.
And one stock — currently priced around $7 — could be the biggest winner. I'll tell you more about the $7 company Huang and Nvidia joined forces with to make it happen. |
12/10/2024
1:38 PM | Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/10/2024
6:15 AM | Olema Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/02/2024
6:15 AM | Olema Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/26/2024
3:48 PM | Graham G. Walmsley (Reporting)
Olema Pharmaceuticals (Issuer)
| Form 4/A | |
11/18/2024
5:00 AM | Kovacs Shane William Charles (Reporting)
Olema Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/14/2024
3:34 PM | Olema Pharmaceuticals (Subject)
Paradigm Biocapital Advisors LP (Filed by)
| Form SC 13G/A | |
11/14/2024
8:20 AM | Deep Track Capital, LP (Filed by)
Olema Pharmaceuticals (Subject)
| Form SC 13G/A | |
09/27/2024
6:00 AM | Olema Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/06/2024
3:15 PM | Olema Pharmaceuticals (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
07/31/2024
4:15 PM | Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/29/2024
3:23 PM | Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/12/2024
4:15 PM | Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/11/2024
11:59 AM | Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/02/2024
4:30 PM | Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/02/2024
3:30 PM | Olema Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
07/02/2024
3:30 PM | Olema Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/28/2024
2:13 PM | Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/18/2024
4:31 PM | BIOTECHNOLOGY VALUE FUND II LP (Reporting)
BIOTECHNOLOGY VALUE FUND L P (Reporting)
Biotechnology Value Trading Fund OS LP (Reporting)
BVF GP HOLDINGS LLC (Reporting)
BVF I GP LLC (Reporting)
BVF II GP LLC (Reporting)
BVF INC/IL (Reporting)
BVF PARTNERS L P/IL (Reporting)
BVF Partners OS Ltd. (Reporting)
LAMPERT MARK N (Reporting)
Olema Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/14/2024
3:39 PM | Olema Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/14/2024
3:34 PM | Olema Pharmaceuticals (Subject)
Point72 Asset Management, L.P. (Filed by)
| Form SC 13G | |
06/06/2024
5:49 PM | Logos Global Management LP (Filed by)
Olema Pharmaceuticals (Subject)
| Form SC 13D/A | |
06/06/2024
9:02 AM | Logos Opportunities Fund I LP (Reporting)
Olema Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/06/2024
9:05 AM | Logos Opportunities Fund II LP (Reporting)
Olema Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/04/2024
8:00 PM | Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/04/2024
2:09 PM | Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/03/2024
1:55 PM | Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/31/2024
11:17 AM | Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/15/2024
6:06 AM | Olema Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/08/2024
3:15 PM | Olema Pharmaceuticals (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
05/07/2024
4:00 PM | Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/06/2024
3:00 PM | Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
Buy OLMA Stock Free OLMA Stock Alerts